GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » Interest Coverage

Launxp Biomedical Co (ROCO:6876) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Launxp Biomedical Co Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Launxp Biomedical Co's Operating Income for the six months ended in Dec. 2024 was NT$-44.08 Mil. Launxp Biomedical Co's Interest Expense for the six months ended in Dec. 2024 was NT$-0.02 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Launxp Biomedical Co's Interest Coverage or its related term are showing as below:


ROCO:6876's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 101.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Launxp Biomedical Co Interest Coverage Historical Data

The historical data trend for Launxp Biomedical Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Launxp Biomedical Co Interest Coverage Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
- - - - -

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Launxp Biomedical Co's Interest Coverage

For the Biotechnology subindustry, Launxp Biomedical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Launxp Biomedical Co's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Launxp Biomedical Co's Interest Coverage falls into.


;
;

Launxp Biomedical Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Launxp Biomedical Co's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Launxp Biomedical Co's Interest Expense was NT$-0.04 Mil. Its Operating Income was NT$-82.30 Mil. And its Long-Term Debt & Capital Lease Obligation was NT$1.11 Mil.

Launxp Biomedical Co did not have earnings to cover the interest expense.

Launxp Biomedical Co's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Launxp Biomedical Co's Interest Expense was NT$-0.02 Mil. Its Operating Income was NT$-44.08 Mil. And its Long-Term Debt & Capital Lease Obligation was NT$1.11 Mil.

Launxp Biomedical Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Launxp Biomedical Co  (ROCO:6876) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Launxp Biomedical Co Interest Coverage Related Terms

Thank you for viewing the detailed overview of Launxp Biomedical Co's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Launxp Biomedical Co Business Description

Traded in Other Exchanges
N/A
Address
10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.

Launxp Biomedical Co Headlines

No Headlines